Accesswire
13 Aug 2026, 11:50 UTC · 1h ago
Microbix Reports Results for Q3 Fiscal 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Accesswire
13 Aug 2026, 11:50 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Year-to-date revenue fell 21% to $11.66 million, driven primarily by a decrease of over $4 million in sales to a Chinese distributor. — Significant YTD revenue decline and reliance on a single volatile international distributor create substantial risk for long-term growth.
-0.60Q3 revenue grew 17% year-over-year to $4.06 million, with antigen revenues increasing by 20%. — The sequential recovery suggests that efforts to diversify the customer base and rebuild from 2025 setbacks are gaining traction.
+0.40Q3 gross margins improved to 54% from 41% in the prior year due to better coverage of fixed manufacturing overhead. — Expanding margins indicate better operational efficiency and potential for a faster path to profitability as sales scale.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The company reported a YTD net loss of $3.4 million, compared to a $765k loss for the same period in 2025. — Widening losses highlight the financial strain caused by the loss of major clients and the cost of rebuilding operations.
-0.30Microbix maintains a strong liquidity position with a current ratio of 6.89 and a low debt-to-equity ratio of 0.40. — Strong balance sheet metrics provide a safety cushion to absorb current losses while pursuing new business development.
+0.20Which stocks this story touches
Q3 revenue and gross margins increased significantly with reduced net losses, although YTD results are weighed down by losses in China.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
37m ago
